Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations.
Cardiovascular risk
Familial combined hyperlipidemia
Friedewald’s equation
Low-density lipoprotein cholesterol
Martin/Hopkins’ equation
Sampson’ equation
Very low-density lipoprotein cholesterol
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
05 May 2021
05 May 2021
Historique:
received:
03
03
2021
accepted:
20
04
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
25
11
2021
Statut:
epublish
Résumé
Sampson et al. developed a novel method to estimate very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) in the setting of hypertriglyceridemia. Familial Combined Hyperlipidemia (FCHL) is a common primary dyslipidemia in which lipoprotein composition interferes with LDL-C estimation. This study aimed to evaluate performance of LDL-C using this new method (LDL-S) compared with LDL-C estimated by Friedewald's and Martin eq. (LDL-F, LDL-M) in FCHL. Data were collected from 340 subjects with confirmed FCHL. Concordance for VLDL-C measured by ultracentrifugation and LDL-C estimated using these measures compared to Sampson's, Martin's and Friedewald's equations was performed using correlation coefficients, root mean squared error (RMSE) and bias. Also, concordance of misclassified metrics according to LDL-C (< 70 and < 100 mg/dL) and Apo B (< 80 and < 65 mg/dL) thresholds were assessed. Sampson's equation was more accurate (RMSE 11.21 mg/dL; R In FCHL, VLDL-C and LDL-C estimation using Sampson's formula showed higher concordance with lipid targets assessed using VLDL-C obtained by ultracentrifugation compared with Friedewald's and Martin's equations. Implementation of Sampson's formula could improve treatment monitoring in FCHL.
Sections du résumé
BACKGROUND
BACKGROUND
Sampson et al. developed a novel method to estimate very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) in the setting of hypertriglyceridemia. Familial Combined Hyperlipidemia (FCHL) is a common primary dyslipidemia in which lipoprotein composition interferes with LDL-C estimation. This study aimed to evaluate performance of LDL-C using this new method (LDL-S) compared with LDL-C estimated by Friedewald's and Martin eq. (LDL-F, LDL-M) in FCHL.
METHODS
METHODS
Data were collected from 340 subjects with confirmed FCHL. Concordance for VLDL-C measured by ultracentrifugation and LDL-C estimated using these measures compared to Sampson's, Martin's and Friedewald's equations was performed using correlation coefficients, root mean squared error (RMSE) and bias. Also, concordance of misclassified metrics according to LDL-C (< 70 and < 100 mg/dL) and Apo B (< 80 and < 65 mg/dL) thresholds were assessed.
RESULTS
RESULTS
Sampson's equation was more accurate (RMSE 11.21 mg/dL; R
CONCLUSIONS
CONCLUSIONS
In FCHL, VLDL-C and LDL-C estimation using Sampson's formula showed higher concordance with lipid targets assessed using VLDL-C obtained by ultracentrifugation compared with Friedewald's and Martin's equations. Implementation of Sampson's formula could improve treatment monitoring in FCHL.
Identifiants
pubmed: 33952259
doi: 10.1186/s12944-021-01471-3
pii: 10.1186/s12944-021-01471-3
pmc: PMC8101115
doi:
Substances chimiques
Apolipoproteins B
0
Cholesterol, LDL
0
Cholesterol, VLDL
0
Triglycerides
0
Cholesterol
97C5T2UQ7J
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
46Références
J Am Coll Cardiol. 2013 Aug 20;62(8):732-9
pubmed: 23524048
Int J Cardiol. 2007 Mar 20;116(2):194-200
pubmed: 16828905
Atherosclerosis. 2018 Oct;277:204-210
pubmed: 29970255
Eur J Prev Cardiol. 2020 Jul;27(10):1088-1090
pubmed: 32013602
Circulation. 2019 Aug 13;140(7):542-552
pubmed: 31216866
JAMA. 2013 Nov 20;310(19):2061-8
pubmed: 24240933
J Am Coll Cardiol. 2016 Jan 19;67(2):193-201
pubmed: 26791067
JAMA Cardiol. 2019 Dec 1;4(12):1287-1295
pubmed: 31642874
Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):274-82
pubmed: 11834528
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Am Coll Cardiol. 2007 Oct 30;50(18):1735-41
pubmed: 17964036
Crit Rev Clin Lab Sci. 2020 Nov;57(7):458-469
pubmed: 32255405
Biomedicines. 2020 Jan 06;8(1):
pubmed: 31935793
Rev Invest Clin. 2018;70(5):224-236
pubmed: 30307446
Int J Stroke. 2018 Aug;13(6):612-632
pubmed: 29786478
Diabetes Spectr. 2018 Aug;31(3):234-245
pubmed: 30140139
JAMA Cardiol. 2018 Aug 1;3(8):749-753
pubmed: 29898218
Clin Chim Acta. 2015 Jan 1;438:160-5
pubmed: 25172037
Atherosclerosis. 2019 Jan;280:1-6
pubmed: 30448567
PLoS One. 2016 Jan 29;11(1):e0148147
pubmed: 26824910
Clin Chem. 2018 Jul;64(7):1006-1033
pubmed: 29760220
Eur J Prev Cardiol. 2015 Oct;22(10):1321-7
pubmed: 25633587
JAMA Cardiol. 2020 May 1;5(5):540-548
pubmed: 32101259
Clin Chem. 2017 Apr;63(4):870-879
pubmed: 28174174